Boston Scientific vs Stryker
Stryker is the larger business, with $25.12bn of revenue in fiscal 2025 against $20.07bn for Boston Scientific (1.3 times as much). Boston Scientific grew faster (19.9% against 11.2%). Boston Scientific kept more of each dollar of sales as profit: a net margin of 14.4% against 12.9%. Boston Scientific carries less debt relative to equity (47.2% against 70.7%).
| Latest fiscal year | Boston ScientificBSX, 2025 | StrykerSYK, 2025 |
|---|---|---|
| Revenue | $20.07bn | $25.12bn |
| Revenue growth | 19.9% | 11.2% |
| Net income | $2.90bn | $3.25bn |
| Operating margin | 18.0% | 19.5% |
| Net margin | 14.4% | 12.9% |
| Return on equity | 12.6% | 15.1% |
| Free cash flow | $3.66bn | $4.28bn |
| Cash | $1.97bn | $4.01bn |
| Total debt | $11.44bn | $15.86bn |
| Debt to equity | 47.2% | 70.7% |
| Dividend per share | — | — |
| Dividend yield | — | 1.1% |
| Share buybacks | — | — |
| Employees | 59,000 | 56,000 |
| Market value | $63.03bn | $118.94bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 73 (Strong) | 78 (Strong) |
| Insider trades, 12 months | 10 buys, 7 sales | 0 buys, 71 sales |